Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Orion Corporation: Organising meeting of the Board of Directors |
| 19 Mar 2013 |
| Transfer of 137,000 own B-shares on 1 March 2013 | 1 Mar 2013 |
| Orion Group Annual Report 2012 and Corporate Governance Statement published | 26 Feb 2013 |
| Orion Group Financial Statement Release for 2012 | 5 Feb 2013 |
| Notice to the Annual General Meeting of Orion Corporation | 5 Feb 2013 |